

## PHARMANUTRA S.P.A. OBTAINS PATENT FOR A NEW COMPOSITION USED FOR TREATING CARDIOVASCULAR DISEASES

The new patent, valid until 2037, opens PharmaNutra up to the possibility of developing specific products for the cardiovascular field, a sector until now unexplored by this Tuscan company.

Pisa, 12<sup>th</sup> November 2019 - PharmaNutra S.p.A. (Aim Italia-Ticker PHN), leading pharmaceutical company in the sector of iron-based oral products, has now announced that it has been granted a patent from the Italian Patents Office on a new composition for use in the prevention and treatment of cardiovascular diseases (N° 102017000085412). Filed in 2017 and entitled by the company "Cardiovascular Formula", the patent will be valid until 2037.

The news of the recently granted patent follows on from the report a week earlier of filing another important patent in the USA, that of Solid Iron, proof once again of the exceptional scientific research and innovative skills of the PharmaNutra Group.

The new formula, developed by the Group's R&D department, is especially effective in the reduction of vascular calcification, laying the foundations for the development of a medical and scientific sector within the company, i.e. that of cardiovascular calcifications, a brand new area for the company and one which affects a much larger scale of the population.

Over recent years, numerous studies have confirmed that calcifications are one of the main causes of cardiovascular diseases, making a significant contribution to the causes of cardiovascular mortality. The new Cardiovascular Formula developed by the Group can therefore represent an effective solution to prevent and counter formation of calcification.

*"This patent crowns a brand new project, developed with the specific objective to find a highly effective formula for the prevention of vascular calcifications. The composition is the result of years of studies, which after impressive results obtained in basic research, are now being extended to the clinical area. The real strength of this new formula, compared to others already available on the market, is the synergy of individual components. Our research has revealed that by combining a number of elements, more benefits can be obtained in the reduction of calcifications, and it is this that makes the difference", commented Germano Tarantino, Chief Scientific Officer of PharmaNutra S.p.A.*

*"As regards iron deficiency in the cardiac field, we are already well-known internationally, thanks to the proven effectiveness of our products in the SiderAL® range. This new patent enables us to*

expand on our research, entering much wider range of medical fields”, added the Group President, **Andrea Lacorte**. “Our objective is to develop not only products used for the prevention of a number of major cardiovascular disorders, but also used to provide an optimal response to the main cardiac treatments, to ensure the correct recovery and return to a healthy and regular lifestyle”.

**PharmaNutra S.p.A.**

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated by numerous clinical studies, 91 of them published and with more than 6000 subjects treated with the supplements. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

<http://www.PharmaNutra.it>

For Information:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b  
56122 Pisa  
Tel. +39 050 7846500  
Fax +39 050 7846524  
[investorrelation@pharmanutra.it](mailto:investorrelation@pharmanutra.it)

**Nomad & Specialist**

**CFO SIM S.p.A.**  
Via dell'Annunciata  
23/4  
20121 Milan  
Tel. +39 02 303431  
[ecm@cfofim.com](mailto:ecm@cfofim.com)

**Press Office**

**Spriano Communication&Partners**  
Tel. +39 02 83635708  
Matteo Russo  
Mob. +39 347 9834881  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
Cristina Tronconi  
Mob. +39 346 0477901  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)